Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Zimmer Holdings

Related ZMH
Zimmer Provides Update On The European Commission Review Process Relating To The Pending Merger With Biomet, Inc.
Zimmer Announces FDA Clearance Of The Stand-alone Optio-C Anterior Cervical System For Use With Structural Allograft/Autograft

In a report published Friday, BMO Capital Markets reiterated its Outperform rating on Zimmer Holdings (NYSE: ZMH), and raised its price target from $80.00 to $82.00.

BMO Capital Markets noted, “ZMH reported 4Q12 revenue of $1,181 million (up 1.1%; up 2.1% ex-fx) versus the consensus estimate of $1,173 million, including two fewer billing days in its EMEA region: Hip sales were $349 million (down 1% ex-fx); Knees $476 million (up 1% ex-fx); Extremities $47 million (up 7% ex-fx); Dental $61 million (down 2%); Trauma $84 million (up 10%); Spine $54 million (down 5%); and Other Surgical Products $110 million (up 19%). EPS of $1.51 (up 10.9%) beat our consensus-matching estimate of $1.49. Management provided 2013 guidance: revenue up 2.5-4.5% ex-fx and EPS of $5.65-$5.85 (versus the Street's $5.74 and our $5.84).”

Zimmer Holdings closed on Thursday at $74.60.

Latest Ratings for ZMH

DateFirmActionFromTo
Dec 2014Leerink SwannMaintainsOutperform
Dec 2014BarclaysMaintainsOverweight
Oct 2014JP MorganMaintainsNeutral

View More Analyst Ratings for ZMH
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings

 

Related Articles (ZMH)

Around the Web, We're Loving...

Get Benzinga's Newsletters